Vitamin B12 for Health & Longevity

Created on 11/08/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Vitamin B12 is an essential vitamin from animal foods, sold as supplements and injections to prevent and correct deficiency, common with age, plant-based eating, stomach surgery, or long-term use of a diabetes drug or stomach-acid blockers. High-dose oral tablets reliably restore levels. With adequate levels, B12 alone has not improved memory or mood; longevity findings come from mice. Risk signals come mostly from vitamin combinations, population studies or case reports. (Full Review)

Protocol

Low-normal or mildly deficient older adults
1,000 µg/day oral
Cyanocobalamin; practical equivalent of 647–1,032 µg/day
Established deficiency, oral route
2,000 µg/day oral
Cyanocobalamin; or 1,000 µg daily for 10 days, then weekly for four weeks, then monthly
Pernicious anemia, injection route
100 µg intramuscularly
Daily for 6–7 days, then on alternate days, then every 3–4 days, followed by 100 µg monthly for life
Time to effect
Reticulocytes
5–10 days
Young red cells rise after treating deficiency
Blood counts
Weeks
Normalize as deficiency anemia is corrected
Nerve improvement
Months
12 months used in the neuropathy trial

Benefits

Contraindications
  • Known cobalt or cobalamin hypersensitivity
  • Early Leber's hereditary optic neuropathy (cyanocobalamin form)
  • Diabetic nephropathy (high-dose combination with folic acid and B6)
  • Within six months after coronary stent placement (combined folic acid, B6 and B12)
  • Men who smoke (long-term single-ingredient B12 above 55 µg/day)
Key Interactions
  • Metformin
  • Proton pump inhibitors (acid-pump blockers: omeprazole)
  • Histamine-2 receptor antagonists (acid reducers: famotidine)
  • Colchicine, para-aminosalicylic acid and heavy alcohol intake
  • Nitrous oxide (anesthetic and recreational gas)
  • High-dose folic acid
  • Folic acid and vitamin B6 (additive supplements)
  • Most antibiotics (e.g., amoxicillin), methotrexate and pyrimethamine
  • Gastric or intestinal surgery, including gastrectomy and bariatric procedures (other intervention)
Theoretical (inferred from mechanism)
  • High-dose vitamin C
  • Betaine (trimethylglycine) and methylfolate

Risk & Side Effects

  • High:
  • Medium:
  • Low: Cancer, especially lung cancer; faster kidney decline in diabetic nephropathy; coronary in-stent restenosis; hospitalization for unstable angina with combined B vitamins; hip fracture with high combined B6 and B12 intake; acneiform eruptions; hypersensitivity and anaphylaxis with injections; peripheral vascular thrombosis and other label-listed reactions; low potassium and heart strain when treating severe anemia; optic atrophy in Leber's hereditary optic neuropathy; aluminum accumulation with prolonged injections in kidney impairment; kidney injury, blood pressure rise and other reactions with high-dose intravenous hydroxocobalamin; higher mortality with high serum B12
  • Speculative: Cyanide load from cyanocobalamin; masked folate deficiency with high doses

Monitoring

Marker Target Why
Serum vitamin B12 Above 400 pg/mL (Life Extension) Confirms repletion
Methylmalonic acid 73–271 nmol/L (standard reference range) Best functional marker of tissue B12
Total homocysteine 5.1–13.9 µmol/L (standard reference range) Reflects combined B12 and folate status
Holotranscobalamin (active B12) About 25–165 pmol/L, assay-dependent (standard reference range) Early marker of active B12
Hemoglobin Women 12.0–15.5 g/dL; men 13.5–17.5 g/dL (standard reference range) Confirms correction of anemia
Mean corpuscular volume (red-cell size) Not specified in the ER Paired with hemoglobin in the blood count
Serum potassium 3.5–5.0 mmol/L (standard reference range) Safety check when treating severe anemia
Kidney filtration rate (diabetic kidney disease only) No established target; track change from own baseline Safety check on high-dose combinations
Folate Not specified in the ER Paired with homocysteine; baseline in at-risk groups
Reticulocytes Not specified in the ER Early response when treating severe anemia
Iron Not specified in the ER Label-listed check before treatment

Cadence: Baseline panel before starting; recheck methylmalonic acid, B12 and blood counts at 8–12 weeks after starting, then every 6–12 months while risk factors persist. When severe anemia is treated, potassium during the first 48 hours and reticulocytes from day 5 to 7.

Qualitative Assessment

  • Energy and exercise tolerance
  • Numbness, tingling or burning in hands and feet
  • Balance and walking steadiness
  • Memory, concentration and processing speed
  • Mood and irritability
  • Mouth or tongue soreness
  • Skin changes such as new acne-like eruptions